Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) for HIV treatment and assess experiences of using Apretude (cabotegravir long-acting (CAB LA) for PrEP) in range of populations

现实世界和实施数据描述了长效Vocabria + Rekambys（卡博特韦+利匹韦林长效制剂 (CAB+RPV LA)）在艾滋病治疗中的有效性，并评估了不同人群中使用Apretude（卡博特韦长效制剂 (CAB LA)用于PrEP）的体验。

New phase IIIb data look at preferences among treatment-naive adults offered the choice to switch to CAB+RPV LA after attaining rapid viral suppression with Dovato (DTG/3TC) daily oral therapy

新型IIIb期数据研究了在使用Dovato（DTG/3TC）每日口服疗法快速实现病毒抑制后，提供转换至CAB+RPV长效疗法选项的初治成人患者的偏好。

Interim data from wave three of the Positive Perspectives study demonstrate impact of joint decision-making on HIV treatment satisfaction and health outcomes

第三波“积极观点”研究的中期数据展示了共同决策对艾滋病治疗满意度和健康结果的影响

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting abstracts from its innovative HIV treatment and prevention portfolio at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda.

GSK plc（LSE/NYSE：GSK）宣布，由GSK控股、辉瑞和盐野义制药为股东的全球专业HIV公司ViiV Healthcare将在卢旺达基加利举行的2025年国际艾滋病学会大会（IAS 2025）上展示其创新HIV治疗和预防组合的摘要。

Key data will highlight the long-term effectiveness of Vocabria & Rekambys, (branded as Cabenuva in the US, Canada and Australia) the company’s complete long-acting injectable regimen for treatment; evaluate patient preference for long-acting injectables compared to daily oral therapy; and measure benefits of long-acting injectables in tackling common challenges associated with taking daily pills, including stigma and adherence..

关键数据将突出Vocabria和Rekambys（在美国、加拿大和澳大利亚 branded 为Cabenuva）的长期有效性，这是公司完整的长效注射治疗方案；评估患者对长效注射剂与每日口服疗法的偏好；并衡量长效注射剂在应对与每日服药相关的常见挑战（包括污名化和依从性）方面的益处。

Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said:

ViiV Healthcare的首席医疗官Jean van Wyk（医学学士，药物流行病学硕士）表示：

“Our extensive real-world insights about CAB+RPV LA for HIV treatment and CAB LA for HIV prevention demonstrate how long-acting injectables are redefining the way we approach HIV care and management in broad populations. The new real-world and implementation data at IAS 2025 further reinforce their effectiveness, safety and tolerability, and underscore our commitment to delivering therapies that meet the evolving needs of people impacted by HIV, offering flexibility and choice beyond daily oral treatment.”.

“我们关于CAB+RPV LA用于HIV治疗和CAB LA用于HIV预防的广泛现实世界见解展示了长效注射剂如何重新定义我们在广大人群中应对HIV护理和管理的方式。在IAS 2025上发布的新现实世界和实施数据进一步证实了它们的有效性、安全性和耐受性，彰显了我们致力于提供满足受HIV影响人群不断变化需求的疗法，为超越每日口服治疗提供了灵活性和选择。”

Key data to be presented at IAS 2025 by ViiV Healthcare and its study partners include:

ViiV Healthcare及其研究合作伙伴将在IAS 2025上展示的关键数据包括：

New data assessing preference and choice to switch to CAB+RPV LA after attaining rapid viral suppression

新数据评估了在快速病毒抑制后转为CAB+RPV LA的偏好和选择。

: First data from the phase IIIb VOLITION study assessed preferences and experiences among ART-naive adults offered the option to switch to CAB+RPV LA after achieving rapid viral suppression with daily

：IIIb期VOLITION研究的首批数据评估了在实现每日快速病毒抑制后，选择转换为CAB+RPV LA的ART初治成年人的偏好和体验。

Dovato

多瓦托

(dolutegravir/lamivudine (DTG/3TC))

（多鲁特格拉韦/拉米夫定 (DTG/3TC)）

1

1

.

。

Growing body of real-world effectiveness data for CAB+RPV LA in broad range of populations

CAB+RPV LA在广泛人群中的实际有效性数据不断增加

:

:

New data will be presented on outcomes including effectiveness, adherence, and satisfaction with CAB+RPV LA, from several real-world studies, including COMBINE-2, and two-year data from CARLOS and BEYOND

来自包括COMBINE-2在内的几项真实世界研究，以及CARLOS和BEYOND的两年数据，将展示有关CAB+RPV LA在疗效、依从性和满意度等方面的结果。

2,3,4,5

2,3,4,5

.

。

In addition, two analyses from the OPERA cohort will focus on the effectiveness of CAB+RPV LA in real-world settings for treatment-experienced adults with viremia at therapy initiation

此外，来自OPERA队列的两项分析将重点关注CAB+RPV LA在治疗开始时有病毒血症的治疗经验丰富的成人中的实际应用效果。

6,7

6,7

.

。

New

新

implementation data on acceptability and benefits of CAB LA for PrEP:

关于CAB LA用于PrEP的可接受性和益处的实施数据：

Data from the PILLAR and EBONI implementation studies will focus on participant experiences with CAB LA implementation among men who have sex with men and transgender men, as well as healthcare provider experiences implementing CAB LA for Black women, respectively

PILLAR 和 EBONI 实施研究的数据将分别关注与男性发生性关系的男性和跨性别男性在CAB LA实施中的参与者体验，以及医疗保健提供者为黑人女性实施CAB LA的经验。

8,9

8,9

.

。

New effectiveness data for

新的有效性数据对于

DTG/3TC in different populations

不同人群中的DTG/3TC

: New data from VOLITION evaluate the efficacy of DTG/3TC in achieving rapid virologic suppression in a diverse treatment-naive population.

：VOLITION的新数据评估了DTG/3TC在实现多样化初治人群快速病毒学抑制方面的疗效。

10

10

Data from investigator-led, ViiV Healthcare-supported studies, D2ARLING and SUNGURA will also be presented, including D2ARLING’s comparison of DTG/3TC effectiveness to other regimens in the presence of transmitted resistance mutations, and an analysis from the SUNGURA study including safety and efficacy data in virally suppressed older people living with HIV switching to DTG/3TC from BIC/FTC/TAF.

由研究者主导、ViiV Healthcare支持的D2ARLING和SUNGURA研究的数据也将被展示，其中包括D2ARLING对DTG/3TC在存在传播性耐药突变的情况下与其他治疗方案的有效性比较，以及来自SUNGURA研究的分析，包括病毒抑制的老年HIV感染者从BIC/FTC/TAF转换到DTG/3TC的安全性和有效性数据。

11,12

11，12

.

。

Positive Perspectives wave three data highlighting the importance of community perspectives in treatment outcomes:

正面视角第三波数据强调了社区视角在治疗结果中的重要性：

Interim results from wave three of the Positive Perspectives study will be presented, showing how shared decision making and treatment satisfaction are linked to treatment outcomes and self-rated health in specific sub-group analyses

Positive Perspectives研究的第三波中期结果将被展示，显示共同决策和治疗满意度如何与特定亚组分析中的治疗结果和自我评定的健康状况相关联。

13

13

. Additionally, the continued need to improve awareness, belief and confidence in U=U will be presented

此外，将继续提出提高对U=U的认知、信念和信心的需求。

14

14

.

。

ViiV Healthcare-sponsored or supported studies to be presented at IAS 2025:

ViiV Healthcare赞助或支持的研究将在IAS 2025上展示：

Title

标题

Presenting author

报告作者

Presentation

报告

CAB+RPV LA

卡博特韦+利匹韦林长效注射剂

Real-world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation

CAB+RPV LA在治疗开始时HIV病毒血症个体中的实际有效性

R. Hsu

徐润华

Oral Abstract OAB0104

口腔摘要 OAB0104

15 July 2025

2025年7月15日

10:45 AM – 11:45 AM CAT

上午10点45分 - 上午11点45分 CAT

24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real‑world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort

每2个月一次的卡博特韦+利匹韦林长效注射在真实世界中的24个月结果：来自德国CARLOS队列中HIV-1感染者的有效性、注射依从性及参与者报告的结果

J. Scherzer

J. 舍尔策

Poster Exhibition TUPEB035

海报展览 TUPEB035

15 July 2025

2025年7月15日

12:00 PM – 13:00 PM CAT

中午12:00 – 下午1:00 CAT

Clinical outcomes among women in the OPERA Cohort initiating CAB+RPV LA with viral loads ≥ 50 copies/mL

在OPERA队列中启动CAB+RPV LA且病毒载量≥50拷贝/mL的女性的临床结果

V. Vannappagari

V. Vannappagari

Poster Exhibition WEPEB036

海报展览 WEPEB036

16 July 2025

2025年7月16日

12:00 PM – 13:00 PM CAT

中午12:00 - 下午1:00 CAT

Perspectives of people with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)

在美国一项观察性真实世界研究（BEYOND）中，HIV感染者（PWH）在转用卡博特韦和利匹韦林长效注射剂（CAB+RPV LA）24个月后的观点

C. Garris

C. 加里斯

Poster Exhibition THPEB036

海报展览 THPEB036

17 July 2025

2025年7月17日

12:00 PM – 13:00 PM CAT

中午12:00 – 下午1:00 CAT

The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in newly diagnosed people living with HIV

选择的力量：在新诊断的HIV感染者中，使用DTG/3TC快速抑制后，强烈偏好CAB+RPV LA。

C. Gutner

C. Gutner

E-Poster EP0170

电子海报 EP0170

High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe

在欧洲COMBINE-2队列中，接受过治疗且病毒学抑制的个体使用长效卡博特韦+利匹韦林后，出现高病毒学抑制率和极少的病毒学失败。

A. Pozniak

A. 波兹尼亚克

E-Poster EP0171

电子海报 EP0171

Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND)

在观察性真实世界研究（BEYOND）中，开始使用卡博特韦和利匹韦林长效注射剂（CAB+RPV LA）后第24个月的临床结果

G. Blick

G. 布利克

E-Poster EP0178

E-Poster EP0178

CAB LA for PrEP

PrEP的CAB LA

One-Year Implementation Outcomes of Cabotegravir Long-Acting Injectable PrEP in Men who Have Sex with Men (MSM) & Transgender Men (TGM): Findings from the PILLAR Study

男男性行为者（MSM）及跨性别男性（TGM）中使用长效注射型卡博特韦预防艾滋病的1年实施结果：来自PILLAR研究的发现

D. Dandachi

D. Dandachi

Poster Exhibition TUPEE116

海报展览 TUPEE116

15 July 2025

2025年7月15日

12:00 PM – 13:00 PM CAT

中午12:00 – 下午1:00 CAT

Health Care Provider Experiences After 12 Months of Implementing Cabotegravir Long-Acting Injectable PrEP (CAB LA) for Black Women: Results from the EBONI Study

实施卡博特韦长效注射型PrEP（CAB LA）12个月后医疗保健提供者的体验：EBONI研究的结果针对黑人女性

Z. Tims-Cook

Z. 蒂姆斯-库克

Poster Exhibition THPEE096

海报展览 THPEE096

17 July 2025

2025年7月17日

12:00 PM – 13:00 PM CAT

中午12:00 - 下午1:00 CAT

DTG/3TC

DTG/3TC

Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: suppression phase outcomes from the phase 3b VOLITION study

使用DTG/3TC快速病毒学抑制有助于初治HIV感染者早期转换为CAB+RPV LA：3b期VOLITION研究的抑制阶段结果

B. Jones

B. 琼斯

Poster Exhibition WEPEB033

海报展览 WEPEB033

16 July 2025

2025年7月16日

12:00 PM – 13:00 PM CAT

中午12:00 – 下午1:00 CAT

Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study

在基线传播性耐药突变的初治HIV感染者中，多洛替韦加拉米夫定的疗效：D2ARLING研究的亚组分析

E. Cordova

E. 科尔多瓦

E-Poster EP0172

电子海报 EP0172

Positive Perspectives

积极的视角

Treatment Satisfaction was Linked to Improved Adherence, and Mental, Physical, Sexual and Overall Health Among People Living with HIV in the Positive Perspectives 3 Study

治疗满意度与改善依从性以及Positive Perspectives 3研究中HIV感染者的心理健康、身体健康、性健康和整体健康相关联。

R. Patel

R. Patel

Poster Exhibition WEPED080

海报展览 WEPED080

16 July 2025

2025年7月16日

12:00 PM – 13:00 PM CAT

中午12:00 – 下午1:00 CAT

Data from the Positive Perspectives 3 Study Highlights the Continued Need for Expansion of Awareness, Belief and Confidence in Undetectable Equals Untransmittable (U=U)

《积极视角3》研究的数据突显了继续扩大对“检测不到=无法传播”（U=U）的认知、信念和信心的必要性。

N. Nwokolo

N. Nwokolo

E-Poster EP0597

电子海报 EP0597

Joint Patient-Provider Decision Making was Associated with Improvements in Quality of Life and Treatment Satisfaction for People Living with HIV in the Positive Perspectives 3 study

在“积极视角3”研究中，共同的患者-医生决策与HIV感染者生活质量及治疗满意度的提升相关。

R. Patel

R. Patel

E-Poster EP0608

电子海报 EP0608

About

关于

Apretude

阿普雷特уд

(cabotegravir long acting)

（卡博特韦长效）

Apretude

阿普雷特уд

is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms.

是一种用于预防性传播HIV-1感染（暴露前预防或PrEP）的药物，适用于体重至少35公斤且感染风险较高的成人和青少年。该药物应与安全性行为措施（如使用避孕套）结合使用。

Apretude

阿普雷特уд

contains the active substance cabotegravir.

含有活性物质卡博特韦。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Apretude 600 mg prolonged-release suspension for injection

Apretude 600 mg 长效注射混悬液

About

关于

Vocabria

卡博特韦

(cabotegravir)

（卡博特韦）

Vocabria

卡博特韦

injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class..

注射剂与利匹韦林注射剂联合使用，用于治疗成人和青少年（至少12岁且体重至少35公斤）的人类免疫缺陷病毒1型（HIV-1）感染，这些患者在稳定的抗逆转录病毒治疗方案下病毒学上得到抑制（HIV-1 RNA <50拷贝/毫升），没有当前或过去对非核苷逆转录酶抑制剂（NNRTI）和整合酶抑制剂（INI）类药物的耐药性证据，且没有因使用这些药物而导致既往病毒学失败。

Vocabria

卡博特韦

tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:.

片剂与利匹韦林片剂联合使用，用于短期治疗 HIV-1 感染的成人和青少年（至少 12 岁且体重至少 35 公斤），这些患者在稳定的抗逆转录病毒治疗方案下病毒学上受到抑制（HIV-1 RNA <50 拷贝/mL），没有当前或过去的证据显示对 NNRTI 和 INI 类药物产生耐药性，并且没有因这些药物导致既往病毒学失败。

oral lead-in to assess tolerability of

口服导入以评估耐受性

Vocabria

卡博特韦

and rilpivirine prior to administration of long acting

在给予长效药物前使用利匹韦林

Vocabria

Vocabria

injection plus long acting rilpivirine injection.

长效利匹韦林注射剂。

oral therapy for adults who will miss planned dosing with

成人计划剂量缺失时的口服治疗方案

Vocabria

卡博特韦

injection plus rilpivirine injection.

注射加利匹韦林注射。

Vocabria

卡博特韦

tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for

片剂仅用于与利匹韦林片剂联合治疗HIV-1，因此，处方信息适用于

Edurant

依度拉韦

(rilpivirine) tablets should also be consulted for recommended dosing.

（利匹韦林）片剂也应咨询推荐的剂量。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的药品特性摘要以获取所有安全信息：

Vocabria

Vocabria

400mg/600 mg prolonged-release suspension for injection and

400毫克/600毫克缓释注射悬液

Vocabria

卡博特韦

30 mg film-coated tablets

30毫克薄膜衣片

About

关于

Rekambys

雷坎比斯

(rilpivirine)

（利匹韦林）

Rekambys

雷坎比斯

is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class..

与卡博特韦注射液联合使用，用于治疗 HIV-1 感染的成人和青少年（至少 12 岁且体重至少 35 公斤），这些患者在稳定的抗逆转录病毒治疗方案下病毒学上受到抑制（HIV-1 RNA < 50 拷贝/mL），没有当前或过去的证据显示对 NNRTI 和 INI 类药物产生病毒耐药性，并且没有因使用这些药物而导致既往病毒学失败。

Rekambys

里卡姆拜斯

should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing.

应始终与卡博特韦注射剂联合使用。推荐的剂量请参阅卡博特韦注射剂的处方信息。

Rekambys

雷坎比斯

may be initiated with oral lead-in or without (direct to injection).

可以通过口服引导开始，也可以不通过口服引导（直接注射）。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Rekambys

雷坎比斯

600mg/900 mg prolonged-release suspension for injection

600毫克/900毫克 长效注射悬液

About

关于

Cabenuva

卡贝努瓦

(cabotegravir + rilpivirine)

（卡博特韦 + 利匹韦林）

Cabenuva

卡贝努瓦

is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine..

适用于成人和12岁及以上且体重至少35公斤的青少年，作为治疗HIV-1感染的完整方案，用于替代当前的抗逆转录病毒治疗方案，适用条件为：在稳定的抗逆转录病毒治疗方案下病毒受到抑制（HIV-1 RNA <50拷贝/毫升），无治疗失败史，且对卡博特韦或利匹韦林无已知或疑似耐药性。

The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland Unlimited Company. Rilpivirine tablets are approved in the US and when used with cabotegravir is indicated for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine..

完整方案结合了由ViiV Healthcare开发的整合酶链转移抑制剂（INSTI）卡博特韦和由杨森科学爱尔兰无限责任公司开发的非核苷逆转录酶抑制剂（NNRTI）利匹韦林。利匹韦林片剂已在美国获批，与卡博特韦联合使用时，适用于短期治疗12岁及以上、体重至少35公斤、病毒学上受到抑制（HIV-1 RNA少于50拷贝/mL）、采用稳定方案、无治疗失败史且对卡博特韦或利匹韦林均无已知或疑似耐药性的成人和青少年的HIV-1感染。

INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse transcriptase, which stops the virus from multiplying..

整合酶抑制剂通过阻止病毒DNA整合到人体免疫细胞（T细胞）的遗传物质中来抑制HIV复制。这一步骤在HIV复制周期中至关重要，也是导致慢性疾病建立的关键。利匹韦林是一种非核苷类逆转录酶抑制剂，通过干扰一种名为逆转录酶的酶起作用，从而阻止病毒增殖。

Please consult the full Prescribing Information

请查阅完整的处方信息

here

这里

.

。

About

关于

Dovato

多瓦托

(dolutegravir and lamivudine)

（多洛特格拉韦和拉米夫定）

Dovato

多瓦托

is indicated as a complete regimen to treat HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25 kg in the US, with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of .

在欧盟，被指示作为完整方案用于治疗12岁以上、体重至少40公斤的成人和青少年的HIV-1感染；在美国，用于体重至少25公斤的个体。适用于无抗逆转录病毒（ARV）治疗史的患者，或用于替代那些病毒学抑制（HIV-1 RNA <50拷贝/mL）且处于稳定ARV治疗方案、无治疗失败史且对任何成分无已知耐药性的患者的当前ARV方案。

Dovato

多瓦托

.

。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Dovato

多瓦托

50 mg/300 mg film-coated tablets

50毫克/300毫克薄膜衣片

.

。

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

商标由ViiV Healthcare集团旗下的公司拥有或许可使用。

About ViiV Healthcare

关于ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012.

ViiV Healthcare是一家全球专业的HIV公司，由葛兰素史克（GSK，伦敦证交所：GSK）和辉瑞（Pfizer，纽约证交所：PFE）于2009年11月成立，致力于为HIV感染者以及可能受益于HIV预防的人们提供治疗和护理的进步。盐野义制药于2012年10月成为ViiV的股东。

The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. .

该公司的目标是比任何公司都更深入、更广泛地关注艾滋病毒和艾滋病，并采取新的方法，提供有效且创新的艾滋病毒治疗和预防药物，同时支持受艾滋病毒影响的社区。如需了解更多关于该公司、其管理团队、产品组合、研发管线和承诺的信息，请访问 viivhealthcare.com。

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。

Cautionary statement regarding forward-looking statements

关于前瞻性声明的警示声明

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q1 Results for 2025..

GSK提醒投资者，GSK所做的任何前瞻性声明或预测，包括本公告中所做的声明，均受可能导致实际结果与预测结果存在重大差异的风险和不确定性影响。这些因素包括但不限于GSK 2024年年度报告Form 20-F中的“风险因素”部分以及GSK 2025年第一季度业绩报告中描述的内容。

References

参考文献

E. Cordova,

E. 科尔多瓦，

et al

等

. Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: suppression phase outcomes from the Phase 3b VOLITION study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

. DTG/3TC快速病毒学抑制有助于初治HIV感染者早期转换为CAB+RPV LA：来自3b期VOLITION研究的抑制期结果。在国际艾滋病学会会议（IAS 2025）上发布，7月13-17日，基加利，卢旺达。

A. Pozniak,

A. 波兹尼亚克，

et al

等人

. High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

在欧洲COMBINE-2队列中，接受长效卡博特韦+利匹韦林治疗的有治疗经验且病毒学抑制的个体表现出高病毒学抑制率和极少的病毒学失败。该研究在国际艾滋病学会会议（IAS 2025）上发布，会议于7月13日至17日在卢旺达基加利举行。

C. Wyen,

C. Wyen，

et al

等

. 24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real‑world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW..

在真实世界环境中，每2个月使用卡博特韦+利匹韦林长效注射的24个月结果：来自德国CARLOS队列中HIV-1感染者的有效性、注射依从性及参与者报告的结果。在国际艾滋病学会会议（IAS 2025）上发表，2025年7月13日至17日，卢旺达基加利。

F. Felizarta,

F. 费利扎塔，

et al

等

. Perspectives of people living with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

在美国一项观察性真实世界研究（BEYOND）中，换用卡博特韦和利匹韦林长效制剂（CAB+RPV LA）24个月后，HIV感染者（PWH）的视角。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

G. Blick,

G. 布利克，

et al

等人

. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

在一项观察性真实世界研究（BEYOND）中，开始使用卡博特韦和利匹韦林长效制剂（CAB+RPV LA）后第24个月的临床结果。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

R. Hsu,

徐 R.

et al

等

. Real-world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

. 在治疗开始时存在HIV病毒血症的个体中，CAB+RPV LA的实际有效性。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

J. Altamirano,

阿尔塔米拉诺，

et al

等

. Clinical outcomes among women in the OPERA cohort initiating CAB+RPV LA with viral loads ≥ 50 copies/mL. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

. OPERA队列中启动CAB+RPV LA治疗且病毒载量≥50拷贝/mL的女性的临床结果。在国际艾滋病学会会议（IAS 2025）上发表，2025年7月13日至17日，卢旺达基加利。

D. Dandachi,

D. Dandachi，

et al

等

. One-year implementation outcomes of cabotegravir long-acting injectable PrEP in men who have sex with men (MSM) & transgender men (TGM): findings from the PILLAR study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

. 长效注射型卡博特韦在男男性行为者（MSM）及跨性别男性（TGM）中的PrEP一年实施结果：PILLAR研究的发现。于国际艾滋病学会大会（IAS 2025）上发表，7月13-17日，基加利，卢旺达。

[1]

[1]

Z. Tims-Cook,

Z. 蒂姆斯-库克，

et al

等

. Health care provider experiences after 12 months of implementing cabotegravir long-acting injectable PrEP (CAB LA) for Black women: EBONI study results. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

实施卡博特韦长效注射PrEP（CAB LA）12个月后医疗保健提供者的体验：EBONI研究结果。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

B. Jones,

B. 琼斯，

et al

等人

. Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: suppression phase outcomes from the phase 3b VOLITION study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

. DTG/3TC快速病毒学抑制有助于初治HIV感染者早期转换为CAB+RPV LA：来自3b期VOLITION研究的抑制期结果。在国际艾滋病学会大会（IAS 2025）上发表，2025年7月13-17日，基加利，卢旺达。

E. Cordova,

E. 科尔多瓦，

et al

等

. Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

多鲁特格拉韦联合拉米夫定在基线传播性耐药突变的初治HIV感染者中的疗效：D2ARLING研究的亚组分析。于国际艾滋病学会会议（IAS 2025）上展示，7月13日至17日，基加利，卢旺达。

L.A. Ombajo,

洛杉矶·翁巴乔，

et al

等人

. Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from the Sungura study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW..

从比克替拉韦/恩曲他滨/替诺福韦阿拉芬酰胺转换为多鲁特格拉韦/拉米夫定双重疗法在病毒抑制的60岁及以上老年人中的疗效与安全性：Sungura研究第24周结果。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

R. Patel,

R. Patel，

et al

等

. Treatment satisfaction was linked to improved adherence, and mental, physical, sexual and overall health among people living with HIV in the Positive Perspectives 3 study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

治疗满意度与改善依从性以及Positive Perspectives 3研究中HIV感染者的心理健康、身体健康、性健康和整体健康相关。该研究在2025年7月13日至17日于卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

R. Patel,

R. Patel,

et al

等

. Data from the Positive Perspectives 3 Study highlights the continued need for expansion of awareness, belief and confidence in undetectable equals untransmittable (U=U). Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

Positive Perspectives 3研究的数据强调了继续扩大对“检测不到等于无法传播”（U=U）的认知、信念和信心的必要性。该研究在2025年7月13日至17日于卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。